Samy also argued that CRISPR’s toolbox could go beyond therapeutics and agriculture as well. For instance, the tool may be used in manufacturing and materials to produce synthetic proteins or enzymes, diagnostics to enable cheap point-of-care diagnostics, microbiome and population health to address antibiotic resistance issues, biodefense and surveillance to track infectious diseases, biofuels and sustainability to rise the efficiency of ethanol production and DNA storage to archive data in DNA sequencing, among others.
Potential investors interested in capturing the innovation in the genomic revolution can turn to theme-specific strategies like the the ARK Genomic Revolution Multi-Sector Fund (NYSEArca: ARKG), which is expected to benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments, improvements and advancements in genomics into their business.
Additionally, ARK Invest’s flagship ARK Innovation Fund (NYSEArca: ARKK) seeks to invest in the cornerstone companies taken from healthcare, technology and industrial sectors that focus on investing in disruptive innovation, which includes those involved in the so-called genomic revolution.
“ARK’s thematic strategies may be a hedge against rapid change that would likely cause turmoil to traditional index strategies,” Winton said.
Additionally, ARK’s innovation-themed ETFs can also provide “low correlation
of relative return to traditional growth strategies can lower risk and increase return over a full market cycle,” Winton added.
Financial advisors who are interested in learning more about the investment opportunities in genomic sequencing can watch the webcast here on demand.